107 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
30 May 24
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
4:08pm
; that the FDA may not ultimately agree with Larimar’s nomabofusp development strategy; the potential impact of public health crises on Larimar’s future clinical
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
may not ultimately agree with Larimar’s nomabofusp development strategy; the potential impact of public health crises on Larimar’s future clinical
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy; the potential impact of public health crises on Larimar’s future
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
clinical trials, and assessments; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy; the potential impact of public
8-K
EX-99.2
bf9j5l tzt9az1georvx
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
PRE 14A
6o3m4f4posy25q52h3mh
12 Apr 24
Preliminary proxy
6:06am
8-K
EX-99.1
565hgalz
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
EX-99.3
qrtprwm gf8rnkvz0pwk
11 Mar 24
Other Events
4:09pm
8-K
EX-99.1
59gaijx2pdopxhj
11 Mar 24
Other Events
4:09pm
8-K
EX-99.2
cno8in e3oc
11 Mar 24
Other Events
4:09pm
424B5
wrnidpbjoa07524f
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
eg4r90pczhhmvo5 csq
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
tgne8jw8
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
ppgg55zxic2
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.3
65kskwj5h c5
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.1
ldrv 8vystm1
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am